18:32 , May 11, 2018 |  BC Week In Review  |  Clinical News

Exicure reports Phase Ib data for psoriasis candidate

Exicure Inc. (Skokie, Ill.) said AST-005 did not significantly decrease echo lucent band thickness compared with placebo in a German Phase Ib trial in 25 patients with chronic plaque psoriasis. The company said echo lucent...
21:29 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Exicure raises additional $11.2M in private placement

On Nov. 6, Exicure Inc. (Skokie, Ill.) said it raised about $11.2 million in the second close of a private financing. The close was led by Luye Pharma Group and included participation from fellow new...
23:44 , Nov 6, 2017 |  BC Extra  |  Financial News

Exicure raises additional $11.2M in private placement

Exicure Inc. (Skokie, Ill.) said it raised about $11.2 million in the second close of a private financing. The close was led by Luye Pharma Group and included participation from fellow new investors Eager Info...
23:18 , Dec 15, 2016 |  BC Week In Review  |  Company News

Exicure, Purdue deal

Exicure granted Purdue exclusive options to license treatments for psoriasis and other diseases amenable to gene regulation. The deal includes an option for worldwide development and commercialization rights to AST-005 , plus three additional targets...
01:16 , Dec 13, 2016 |  BC Extra  |  Company News

Purdue in deal for Exicure's lead program in psoriasis

Gene regulation company Exicure Inc. (Skokie, Ill.) granted Purdue Pharma L.P. (Stamford, Conn.) exclusive, worldwide rights to its anti- tumor necrosis factor (TNF) candidate AST-005 and options to in-license therapeutic candidates against three other targets...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

AST-005: Phase I started

Exicure began a Phase I trial to evaluate AST-005 topical gel in 15 patients. Exicure Inc. , Skokie, Ill.   Product: AST-005   Business: Autoimmune   Molecular target: Tumor necrosis factor (TNF)   Description: Topical...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)

Infectious disease INDICATION: Viral infection Patient sample and mouse studies suggest TNF inhibitors could help treat chronic viral infections involving loss of CD4+ T cell function. In blood from HIV patient samples and a mouse...